The three-injection recombinant new crown vaccine is on the market and has been approved for emergency use in China

By yqqlm yqqlm

New Beijing News (Reporter Wu Tingting) Today (May 12), the reporter learned from the Beijing Economic Development Zone that the new crown vaccine”Chikweide” has been successfully rolled off the line on May 3 Listed. The New Coronary Vaccine product has been approved for emergency use in China. It is a recombinant subunit vaccine that uses a three-dose immunization program.

The new crown vaccine”Zikeweide” jointly developed by Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences, uses Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. (hereinafter referred to as Zhifei Lvzhu) Existing advanced production and packaging lines, expanding production capacity. On May 3, the first batch of COVID-19 vaccines were successfully rolled off the market.

Zhifei Lvzhu is located in Beijing Economic Development Zone. It is a high-tech enterprise integrating research and development, production and sales of new vaccines. The reporter learned that”Smart Weed” takes the receptor binding domain (RBD) of the new coronavirus S protein as its target, and induces the human body to produce neutralizing antibodies by recombinantly expressing the RBD protein, thereby blocking the new coronavirus and Host cell surface receptor ACE2 binds to achieve the purpose of preventing infection. This vaccine uses genetic recombination technology to express specific antigens. The technology is advanced and mature. It can be stored for 24 months in a dark environment at 2°C to 8°C. It is easier to transport and store normally, and increases the accessibility of the vaccine.

The Phase II clinical trial of the”Chik Weide” Covid-19 vaccine in adults aged 18-59 shows that Subjects received 2 doses of Zhikweide, the neutralizing antibody positive conversion rate reached 83%, and after the subjects received 3 doses of Zhikweide, the neutralizing antibody positive conversion rate reached 97%. A phase I trial in elderly people aged 60 years and older showed that after subjects received 3 doses of Zhikweide, the positive conversion rate of neutralizing antibodies reached 95%; no serious adverse reactions related to the vaccine occurred, which proved this The vaccine has good safety and effectiveness, and can be vaccinated for the elderly 60 years and older.

Next, the Beijing Economic and Technological Development Zone will continue to make every effort to ensure the production of the new crown vaccine for Zhifei Green Bamboo, and help construct Immune barrier.

Beijing News reporter Wu Tingting

Editor Bai Shuang Proofread Lucy